Podrobno

Izdelava trdnih disperzij fenofibrata s koprocesirano pomožno snovjo in stiskanje orodisperzibilnih tablet
ID Pačnik, Nejc (Avtor), ID Planinšek, Odon (Mentor) Več o mentorju... Povezava se odpre v novem oknu, ID Baumgartner, Ana (Komentor)

.pdfPDF - Predstavitvena datoteka, prenos (2,37 MB)
MD5: 175BA0D8350DC7491E6445E5C39C73D6

Izvleček
Peroralna uporaba zdravil ostaja preferenčna zaradi enostavnosti in dobrega sodelovanja pacientov. Razvoj formulacij za peroralno aplikacijo velikokrat predstavlja izziv, saj je velik delež novih učinkovin v vodi slabo topnih. Eden od pristopov za izboljšanje topnosti in hitrosti raztapljanja ter posledično biološke uporabnosti takšnih učinkovin je priprava trdnih disperzij, saj s tem dosežemo njihovo pretvorbo v amorfno stanje. Ta način je primeren tudi za slabo topno učinkovino fenofibrat, ki jo uporabljamo za zmanjšanje koncentracije maščob v krvi. Cilj naše raziskave je bil izboljšati raztapljanje fenofibrata z izdelavo trdne disperzije s koprocesirano pomožno snovjo. Ta je sestavljena iz mezoporoznega silicijevega dioksida, ki smo ga granulirali z izomaltom. S tem smo izboljšali stisljivost in pretočnost delcev silicijevega dioksida, da smo lažje oblikovali končno farmacevtsko obliko, orodisperzibilne tablete. Z metodo odparevanja topila smo izdelali več različnih trdnih disperzij, ki so se razlikovale v uporabljenem topilu (aceton oziroma izopropanol) in temperaturi odparevanja topila (40 °C oziroma 70 °C). V trdnih disperzijah smo spreminjali tudi vsebnost, ki je znašala od 20 % do 50 % fenofibrata. Za vse izdelane trdne disperzije smo opravili termično analizo in test sproščanja v pufru s pH 1,2 ter ugotovili, da lahko na ta način dosežemo amorfizacijo učinkovine in izboljšamo sproščanje glede na čisti fenofibrat in njegove fizikalne zmesi s silicijevim dioksidom. Glede na rezultate sproščanja in rezultate diferenčne dinamične kalorimetrije smo za izdelavo orodisperzibilnih tablet z direktnim stiskanjem izbrali 30 % trdno disperzijo fenofibrata, pripravljeno z acetonom pri 70 °C. Z dodatkom 10 % superrazgrajevala natrijeve kroskarmeloze, 10 % manitola in 1 % magnezijevega stearata smo izdelali orodisperzibilne tablete in se uspešno približali profilu sproščanja čiste trdne disperzije. Po 5 tednih hranjenja vzorcev v hladilniku oz. pri temperaturi 40 °C in relativni vlagi 75 % smo preverili tudi stabilnost trdnih disperzij. Ugotovili smo, da povišana temperatura in relativna vlažnost znatno poslabšata stabilnost, medtem ko so vzorci v hladilniku v večini primerov ohranili svoje lastnosti. Pri izdelanih trdnih disperzijah uporabljeno topilo in temperatura odparevanja topila nista bistveno vplivala na rezultate sproščanja in analize z DSC.

Jezik:Slovenski jezik
Ključne besede:trdna disperzija, fenofibrat, mezoporozni silicijev dioksid, koprocesirana pomožna snov, orodisperzibilne tablete
Vrsta gradiva:Magistrsko delo/naloga
Organizacija:FFA - Fakulteta za farmacijo
Leto izida:2023
PID:20.500.12556/RUL-153044 Povezava se odpre v novem oknu
Datum objave v RUL:15.12.2023
Število ogledov:646
Število prenosov:102
Metapodatki:XML DC-XML DC-RDF
:
PAČNIK, Nejc, 2023, Izdelava trdnih disperzij fenofibrata s koprocesirano pomožno snovjo in stiskanje orodisperzibilnih tablet [na spletu]. Magistrsko delo. [Dostopano 17 april 2025]. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=153044
Kopiraj citat
Objavi na:Bookmark and Share

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Production of fenofibrate solid dispersions with coprocessed excipient and compression of orodispersible tablets
Izvleček:
Oral use remains preferable due to ease of use and patient compliance. However, development of oral formulations often presents a challenge, since approximately 40% of newly discovered active pharmaceutical ingredients are poorly water-soluble. To improve solubility and thereby bioavailability of such drugs, a great option remains formulation of amorphous solid disperisons. This approach is also suitable for the poorly soluble fenofibrate, which is used to lower the amount of fatty substances in blood. The aim of our research was to improve dissolution of fenofibrate by making solid dispersions with coprocessed excipient, which consisted of mesoporous silica, granulated with isomalt. Co-processing significantly improved compressibility and flowability of pure silica, which made it easier to produce final dosage form, orodispersible tablets. Solvent evaporation method was used to produce solid dispersions, which differed in the use of the solvent (acetone or isopropanol) and the solvent evaporation temperature (40 °C or 70 °C). We also varied the content of active ingredient in solid dispersions with 50%, 40%, 30% or 20% of fenofibrate. Solid dispersions were evaluated by thermic analysis and dissolution tests in buffer of pH 1.2 as the dissolution medium. Drug amorphisation as well as improved dissolution was achieved compared to dissolution of pure fenofibrate and physical mixtures. Based on results of dissolution testing and results of thermic analysis, solid dispersion containing 30% of fenofibrate prepared with acetone at 70 °C was chosen to formulate orodispersible tablets with direct compression. By adding 10% of superdisintegrant sodium croscarmellose, 10% of mannitol and 1% of magnesium stearate to formulation, the dissolution profile of tablets came close to the dissolution profiles of pure solid dispersion. After 5 weeks of storage in refrigerator and at 40 °C and 75% relative humidity, stability of prepared solid dispersions was evaluated as well. Elevated temperature and relative humidity significantly affected stability, while the samples stored in a refrigerator had comparable characteristics as freshly prepared samples. The solvent used and the solvent evaporation temperature did not significantly affect the results of dissolution testing and of thermic analysis.

Ključne besede:solid dispersion, fenofibrate, mesoporous silica, coprocessed excipient, orodispersible tablets

Podobna dela

Podobna dela v RUL:
  1. Isolation and antimicrobial activity of colicins E1 and E4 of bacterium Escherichia coli
  2. Prevalence and associations of tcpC, a gene encoding a Toll/Interleukin-1 receptor domain-containing protein, among Escherichia coli urinary tract infection, skin and soft tissue infection, and commensal isolates
  3. Optimization of different sized plasmid DNA production in a bioreactor
  4. Escherichia coli isolated from cases of colibacillosis in Russian poultry farms (Perm Krai)
  5. Benzamide derivatives targeting the cell division protein FtsZ
Podobna dela v drugih slovenskih zbirkah:
  1. Non O157:H7 avian pathogenic Shiga toxin-producing Escherichia coli isolated from lesions on broiler chickens in Brazil
  2. Enterohemorrhagic Escherichia coli O157
  3. Molecules involved in motility regulation in Escherichia coli cells
  4. Crystal structure of human PCNA in complex with three p15 peptides
  5. Structural basis of human clamp sliding on DNA

Nazaj